1027915-16-7

Basic information

• Product Name: 6-Bromo-4,4-dimethyl-chroman
• Synonyms: 6-Bromo-4,4-dimethyl-chroman;6-Bromo-3,4-dihydro-4,4-dimethyl-2H-1-benzopyran
• CAS NO: 1027915-16-7
• Molecular Formula: C11H13BrO
• Molecular Weight: 241.13
• Mol File: 1027915-16-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Bromo-4,4-dimethyl-chroman(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-4,4-dimethyl-chroman(1027915-16-7)
• EPA Substance Registry System: 6-Bromo-4,4-dimethyl-chroman(1027915-16-7)

Safety Data

• Hazardous Substances Data: 1027915-16-7(Hazardous Substances Data)

Usage

General Description

6-Bromo-4,4-dimethyl-chroman is a chemical compound with the molecular formula C12H15BrO. It is a derivative of chroman, a type of organic compound with a six-membered ring containing an oxygen atom. This chemical exists as a colorless to pale yellow liquid and is insoluble in water but soluble in organic solvents. It is used in the pharmaceutical and chemical industries as a reagent in the synthesis of various compounds. Additionally, it has potential applications in the field of organic chemistry research and as a building block for the development of new molecules with specific properties or functions.

Upstream product

• 49660-57-3 6-bromochroman-4-one 
• 544-97-8 dimethyl zinc(II) 
• 42007-25-0 diphenyl 3-methyl-3-buten-1-yl phosphate 
• 106-41-2 4-bromo-phenol 
• 870-63-3 prenyl bromide 
• 1254733-86-2 4-bromophenyl 3-methylbut-3-en-1-yl ether 

Downstream Products

• 107430-96-6 4,4-dimethylchromane-6-carbaldehyde 
• 1350758-51-8 4-{8-[(4,4-dimethyl-3,4-dihydro-2H-chromen-6-yl)methyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl}benzoic acid trifluoroacetate 
• 1350762-37-6 C₂₇H₃₂N₂O₄ 

Relevant articles and documents

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

Development of chromanes as novel inhibitors of the uncoupling proteins

The uncoupling proteins (UCPs) are mitochondrial carriers that modulate the energetic efficiency and, as a result, can lower superoxide levels. Here, we describe the discovery of a small-molecule inhibitor of the UCPs. Screening of potential UCP1 regulators led to the identification of chromane derivatives that inhibit its proton conductance. Members of the UCP family can act as a defense against oxidative stress and, thus, UCP2 plays a protective role in tumor cells. High UCP2 levels have been associated with chemoresistance. We demonstrate that chromanes also inhibit UCP2 and, in HT-29 human carcinoma cells, cause oxidative stress. The chromane derivatives can act synergistically with chemotherapeutic agents; for instance, they increase the toxicity of arsenic trioxide in HT-29 cells. These findings open a promising line in the development of novel anticancer agents.